Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech ...

Misperceptions and a focus on weight-loss medications risk oversimplifying a complex health crisis. Read more at straitstimes ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

Here are Investing.com’s stocks of the week. Microsoft was one of many tech giants that reported earnings this week, with the company topping profit and revenue expectations. MSFT shares jumped more ...